SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Hi Tech Pharmacal Co Inc – ‘10-Q’ for 10/31/12 – ‘EX-101.CAL’

On:  Friday, 12/7/12, at 11:38am ET   ·   For:  10/31/12   ·   Accession #:  1193125-12-494838   ·   File #:  0-20424

Previous ‘10-Q’:  ‘10-Q’ on 9/10/12 for 7/31/12   ·   Next:  ‘10-Q’ on 3/8/13 for 1/31/13   ·   Latest:  ‘10-Q’ on 3/11/14 for 1/31/14

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

12/07/12  Hi Tech Pharmacal Co Inc          10-Q       10/31/12   69:4.1M                                   Donnelley … Solutions/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    407K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     25K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     25K 
 4: EX-32       Certification -- §906 - SOA'02                      HTML     19K 
47: R1          Document and Entity Information                     HTML     39K 
36: R2          Condensed Consolidated Balance Sheets               HTML    121K 
44: R3          Condensed Consolidated Balance Sheets               HTML     39K 
                (Parenthetical)                                                  
49: R4          Condensed Consolidated Statements of Operations     HTML     97K 
                (Unaudited)                                                      
64: R5          Condensed Consolidated Statements of Comprehensive  HTML     35K 
                Income (Unaudited)                                               
38: R6          Condensed Consolidated Statements of Cash Flows     HTML     87K 
43: R7          Basis of Presentation                               HTML     30K 
32: R8          Business                                            HTML     23K 
23: R9          Revenue Recognition                                 HTML     22K 
65: R10         Net Income Per Share                                HTML     24K 
51: R11         Accounts Receivable                                 HTML     57K 
50: R12         Inventory                                           HTML     29K 
55: R13         Property and Equipment                              HTML     35K 
56: R14         Intangible Assets                                   HTML     63K 
54: R15         Long-Term Debt                                      HTML     26K 
57: R16         Freight Expense                                     HTML     21K 
46: R17         Stock-Based Compensation                            HTML     46K 
48: R18         Product Divestitures                                HTML     23K 
53: R19         Income Taxes                                        HTML     27K 
69: R20         Contingencies and Other Matters                     HTML     47K 
60: R21         Recent Accounting Pronouncements                    HTML     28K 
40: R22         Significant Customers and Concentration of Credit   HTML     26K 
                Risk                                                             
52: R23         Fair Value Measurements                             HTML     42K 
42: R24         Segment Information                                 HTML     77K 
17: R25         Subsequent Events                                   HTML     22K 
61: R26         Accounts Receivable (Tables)                        HTML     53K 
66: R27         Inventory (Tables)                                  HTML     27K 
27: R28         Property and Equipment (Tables)                     HTML     33K 
26: R29         Intangible Assets (Tables)                          HTML     52K 
30: R30         Stock-Based Compensation (Tables)                   HTML     43K 
31: R31         Fair Value Measurements (Tables)                    HTML     37K 
33: R32         Segment Information (Tables)                        HTML     72K 
16: R33         Net Income Per Share (Details)                      HTML     20K 
58: R34         Accounts Receivable (Details)                       HTML     29K 
39: R35         Accounts Receivable (Details 1)                     HTML     33K 
41: R36         Accounts Receivable (Details Textual)               HTML     22K 
20: R37         Inventory (Details)                                 HTML     29K 
68: R38         Property and Equipment (Details)                    HTML     35K 
11: R39         Property and Equipment (Details Textual)            HTML     28K 
34: R40         Intangible Assets (Details)                         HTML     56K 
63: R41         Intangible Assets (Details Textual)                 HTML    108K 
19: R42         Long-Term Debt (Details)                            HTML     46K 
25: R43         Freight Expense (Details)                           HTML     21K 
29: R44         Stock-Based Compensation (Details)                  HTML     28K 
37: R45         Stock Based Compensation (Details 1)                HTML     37K 
15: R46         Stock-Based Compensation (Details Textual)          HTML     43K 
22: R47         Product Divestitures (Details)                      HTML     36K 
13: R48         Income Taxes (Details)                              HTML     26K 
62: R49         Contingencies and Other Matters (Details)           HTML     66K 
18: R50         Significant Customers and Concentration of Credit   HTML     26K 
                Risk (Details)                                                   
59: R51         Fair Value Measurements (Details)                   HTML     24K 
21: R52         Fair Value Measurements (Details 1)                 HTML     26K 
35: R53         Fair Value Measurements (Details Textual)           HTML     21K 
12: R54         Segment Information (Details)                       HTML     39K 
14: R55         Segment Information (Details Textual)               HTML     20K 
28: R56         Subsequent Events (Details)                         HTML     36K 
67: XML         IDEA XML File -- Filing Summary                      XML     99K 
24: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS    601K 
 5: EX-101.INS  XBRL Instance -- hitk-20121031                       XML    903K 
 7: EX-101.CAL  XBRL Calculations -- hitk-20121031_cal               XML    125K 
 8: EX-101.DEF  XBRL Definitions -- hitk-20121031_def                XML    274K 
 9: EX-101.LAB  XBRL Labels -- hitk-20121031_lab                     XML    809K 
10: EX-101.PRE  XBRL Presentations -- hitk-20121031_pre              XML    540K 
 6: EX-101.SCH  XBRL Schema -- hitk-20121031                         XSD    153K 
45: ZIP         XBRL Zipped Folder -- 0001193125-12-494838-xbrl      Zip     94K

‘EX-101.CAL’   —   XBRL Calculations — hitk-20121031_cal

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- XBRL document created with Crossfire by Rivet Software version 4.3.96.0 http://www.rivetsoftware.com -->
<!-- Based on XBRL 2.1 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.hitechpharm.com/2011-03-31/role/StatementCondensedConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.hitechpharm.com/2011-03-31/role/StatementCondensedConsolidatedStatementsOfOperations"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.hitechpharm.com/2011-03-31/role/StatementCondensedConsolidatedStatementsOfCashFlows"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#NetIncomePerShareDetails" roleURI="http://www.hitechpharm.com/role/NetIncomePerShareDetails"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#InventoryDetails" roleURI="http://www.hitechpharm.com/role/InventoryDetails"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#PropertyAndEquipmentDetails" roleURI="http://www.hitechpharm.com/role/PropertyAndEquipmentDetails"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#InventoryTables" roleURI="http://www.hitechpharm.com/role/InventoryTables"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#PropertyAndEquipmentTables" roleURI="http://www.hitechpharm.com/role/PropertyAndEquipmentTables"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#PropertyAndEquipmentTextual" roleURI="http://www.hitechpharm.com/role/PropertyAndEquipmentTextual"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#IntangibleAssetsDetails" roleURI="http://www.hitechpharm.com/role/IntangibleAssetsDetails"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#IntangibleAssetsTables" roleURI="http://www.hitechpharm.com/role/IntangibleAssetsTables"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#LongTermDebtDetails" roleURI="http://www.hitechpharm.com/role/LongTermDebtDetails"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#FreightExpenseDetails" roleURI="http://www.hitechpharm.com/role/FreightExpenseDetails"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#StockBasedCompensationTables" roleURI="http://www.hitechpharm.com/role/StockBasedCompensationTables"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#StockBasedCompensationDetails" roleURI="http://www.hitechpharm.com/role/StockBasedCompensationDetails"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#StockBasedCompensationDetailsTextual" roleURI="http://www.hitechpharm.com/role/StockBasedCompensationDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#IntangibleAssetsTextual" roleURI="http://www.hitechpharm.com/role/IntangibleAssetsTextual"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#ProductDivestituresDetails" roleURI="http://www.hitechpharm.com/role/ProductDivestituresDetails"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#IncomeTaxesDetails" roleURI="http://www.hitechpharm.com/role/IncomeTaxesDetails"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#ContingenciesAndOtherMattersDetails" roleURI="http://www.hitechpharm.com/role/ContingenciesAndOtherMattersDetails"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#SignificantCustomersAndConcentrationOfCreditRiskDetails" roleURI="http://www.hitechpharm.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#FairValueMeasurementsTables" roleURI="http://www.hitechpharm.com/role/FairValueMeasurementsTables"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#FairValueMeasurementsDetails" roleURI="http://www.hitechpharm.com/role/FairValueMeasurementsDetails"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#FairValueMeasurementsDetailsTextual" roleURI="http://www.hitechpharm.com/role/FairValueMeasurementsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#ConsolidatedStatementsOfComprehensiveIncome" roleURI="http://www.hitechpharm.com/role/ConsolidatedStatementsOfComprehensiveIncome"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#SegmentInformationDetails" roleURI="http://www.hitechpharm.com/role/SegmentInformationDetails"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#SegmentInformation" roleURI="http://www.hitechpharm.com/role/SegmentInformation"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#AccountsReceivable" roleURI="http://www.hitechpharm.com/role/AccountsReceivable"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#AccountsReceivableTables" roleURI="http://www.hitechpharm.com/role/AccountsReceivableTables"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#AccountsReceivableDetails" roleURI="http://www.hitechpharm.com/role/AccountsReceivableDetails"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#AccountsReceivableDetails1" roleURI="http://www.hitechpharm.com/role/AccountsReceivableDetails1"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#AccountsReceivableDetailsTextual" roleURI="http://www.hitechpharm.com/role/AccountsReceivableDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#SegmentInformationDetailsTextual" roleURI="http://www.hitechpharm.com/role/SegmentInformationDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#SubsequentEvents" roleURI="http://www.hitechpharm.com/role/SubsequentEvents"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#SubsequentEventsDetails" roleURI="http://www.hitechpharm.com/role/SubsequentEventsDetails"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#StockBasedCompensationDetails1" roleURI="http://www.hitechpharm.com/role/StockBasedCompensationDetails1"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#FairValueMeasurementsDetailsOne" roleURI="http://www.hitechpharm.com/role/FairValueMeasurementsDetailsOne"/>
<roleRef xlink:type="simple" xlink:href="hitk-20121031.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.hitechpharm.com/2011-03-31/role/DocumentDocumentAndEntityInformation"/>
<calculationLink xlink:role="http://www.hitechpharm.com/2011-03-31/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="0110 - Statement - Condensed Consolidated Balance Sheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_634668043243399027" order="20" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_634668043243399027" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_634668043243399027" order="20" use="optional" weight="1" priority="3"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_634668043243399027" xlink:to="us-gaap_AccountsReceivableNetCurrent_634668043243399027" order="40" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_634668043243399027" xlink:to="us-gaap_InventoryNet_634668043243399027" order="60" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_634668043243399027" xlink:to="us-gaap_PrepaidTaxes_634668043243399027" order="100" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_634668043243399027" xlink:to="us-gaap_OtherAssetsCurrent_634668043243399027" order="120" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_634668043243399027" order="40" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_634668043243399027" order="60" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrent_634668043243399027" order="80" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_634668043243399027" order="100" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_634668043243399027" order="20" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_634668043243399027" xlink:to="us-gaap_LiabilitiesCurrent_634668043243399027" order="20" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_634668043243399027" xlink:to="us-gaap_AccountsPayableCurrent_634668043243399027" order="20" use="optional" weight="1" priority="3"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_634668043243399027" xlink:to="us-gaap_AccruedLiabilitiesCurrent_634668043243399027" order="40" use="optional" weight="1" priority="3"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_634668043243399027" xlink:to="us-gaap_LongTermDebtCurrent_634668043243399027" order="60" use="optional" weight="1" priority="3"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_634668043243399027" order="40" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_634668043243399027" xlink:to="us-gaap_PreferredStockValue_634668043243399027" order="20" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_634668043243399027" xlink:to="us-gaap_CommonStockValue_634668043243399027" order="40" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_634668043243399027" xlink:to="us-gaap_AdditionalPaidInCapital_634668043243399027" order="60" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_634668043243399027" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_634668043243399027" order="80" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_634668043243399027" xlink:to="us-gaap_TreasuryStockValue_634668043243399027" order="100" use="optional" weight="-1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_634668043243399027" xlink:to="us-gaap_DeferredTaxAssetsNetCurrent_634668043243399027" order="80" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_634668043243399027" xlink:to="us-gaap_LongTermDebtNoncurrent_634668043243399027" order="60" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="hitk-20121031.xsd#hitk_CurrentPortionOfContingentPaymentLiability" xlink:label="hitk_CurrentPortionOfContingentPaymentLiability"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_634668043243399027" xlink:to="hitk_CurrentPortionOfContingentPaymentLiability" order="65" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="hitk-20121031.xsd#hitk_ContingentPaymentLiabilityNetOfCurrentPortion" xlink:label="hitk_ContingentPaymentLiabilityNetOfCurrentPortion"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_634668043243399027" xlink:to="hitk_ContingentPaymentLiabilityNetOfCurrentPortion" order="40" use="optional" weight="1" priority="1"/>
</calculationLink>
<calculationLink xlink:role="http://www.hitechpharm.com/2011-03-31/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="0120 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_634668043243711031"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_634668043243711031"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_634668043243711031" xlink:to="us-gaap_IncomeTaxExpenseBenefit_634668043243711031" order="40" use="optional" weight="-1" priority="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_634668043243711031"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_634668043243711031" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_634668043243711031" order="20" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_634668043243711031"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_634668043243711031"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_634668043243711031" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_634668043243711031" order="20" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_634668043243711031" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="40" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_634668043243711031"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_634668043243711031" xlink:to="us-gaap_NonoperatingIncomeExpense_634668043243711031" order="20" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_634668043243711031"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_634668043243711031" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_634668043243711031" order="20" use="optional" weight="-1" priority="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherDepreciationAndAmortization" xlink:label="us-gaap_OtherDepreciationAndAmortization"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_634668043243711031" xlink:to="us-gaap_OtherDepreciationAndAmortization" order="30" use="optional" weight="-1" priority="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_634668043243711031"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_634668043243711031" xlink:to="us-gaap_ResearchAndDevelopmentExpense_634668043243711031" order="40" use="optional" weight="-1" priority="1"/>
<loc xlink:type="locator" xlink:href="hitk-20121031.xsd#hitk_RoyaltyIncomeExpense" xlink:label="hitk_RoyaltyIncomeExpense_634668043243711031"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_634668043243711031" xlink:to="hitk_RoyaltyIncomeExpense_634668043243711031" order="60" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_634668043243711031"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_634668043243711031" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_634668043243711031" order="80" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_634668043243711031"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_634668043243711031" xlink:to="us-gaap_InterestExpense_634668043243711031" order="100" use="optional" weight="-1" priority="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome_634668043243711031"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_634668043243711031" xlink:to="us-gaap_InterestAndOtherIncome_634668043243711031" order="120" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_634668043243711031"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_634668043243711031" xlink:to="us-gaap_GrossProfit_634668043243711031" order="40" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet_634668043243711031"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_634668043243711031" xlink:to="us-gaap_SalesRevenueNet_634668043243711031" order="20" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_634668043243711031"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_634668043243711031" xlink:to="us-gaap_CostOfGoodsAndServicesSold_634668043243711031" order="40" use="optional" weight="-1" priority="1"/>
</calculationLink>
<calculationLink xlink:role="http://www.hitechpharm.com/2011-03-31/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="0140 - Statement - Condensed Consolidated Statements of Cash Flows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_634668043243399027" order="20" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_634668043243399027" order="40" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_634668043243399027" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_634668043243399027" order="20" use="optional" weight="-1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_634668043243399027" xlink:to="us-gaap_ProceedsFromSaleOfIntangibleAssets_634668043243399027" order="40" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_634668043243399027" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_634668043243399027" order="60" use="optional" weight="-1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_634668043243399027" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets_634668043243399027" order="80" use="optional" weight="-1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_634668043243399027" order="60" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_634668043243399027" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_634668043243399027" order="20" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_634668043243399027"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_634668043243399027" xlink:to="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_634668043243399027" order="60" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt_634668043243555029"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_634668043243399027" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt_634668043243555029" order="80" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_634668043243399027" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" order="100" use="optional" weight="-1" priority="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/NetIncomePerShareDetails" xlink:title="0604 - Disclosure - Net Income Per Share (Details)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/InventoryDetails" xlink:title="0606 - Disclosure - Inventory (Details)">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_InventoryNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_InventoryRawMaterials"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_InventoryNet" xlink:to="loc_InventoryRawMaterials" order="20" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_InventoryWorkInProcess"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_InventoryNet" xlink:to="loc_InventoryWorkInProcess" order="40" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_InventoryFinishedGoods"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_InventoryNet" xlink:to="loc_InventoryFinishedGoods" order="60" use="optional" weight="1" priority="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/PropertyAndEquipmentDetails" xlink:title="0607 - Disclosure - Property and Equipment (Details)">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_PropertyPlantAndEquipmentGross"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PropertyPlantAndEquipmentNet" xlink:to="loc_PropertyPlantAndEquipmentGross" order="20" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PropertyPlantAndEquipmentNet" xlink:to="loc_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="40" use="optional" weight="-1" priority="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/InventoryTables" xlink:title="0506 - Disclosure - Inventory (Tables)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/PropertyAndEquipmentTables" xlink:title="0507 - Disclosure - Property and Equipment (Tables)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/PropertyAndEquipmentTextual" xlink:title="06071 - Disclosure - Property and Equipment (Details Textual)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/IntangibleAssetsDetails" xlink:title="0608 - Disclosure - Intangible Assets (Details)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/IntangibleAssetsTables" xlink:title="0508 - Disclosure - Intangible Assets (Tables)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/LongTermDebtDetails" xlink:title="0609 - Disclosure - Long-Term Debt (Details)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/FreightExpenseDetails" xlink:title="0610 - Disclosure - Freight Expense (Details)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/StockBasedCompensationTables" xlink:title="0511 - Disclosure - Stock-Based Compensation (Tables)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/StockBasedCompensationDetails" xlink:title="0611 - Disclosure - Stock-Based Compensation (Details)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/StockBasedCompensationDetailsTextual" xlink:title="06112 - Disclosure - Stock-Based Compensation (Details Textual)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/IntangibleAssetsTextual" xlink:title="06081 - Disclosure - Intangible Assets (Details Textual)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/ProductDivestituresDetails" xlink:title="0612 - Disclosure - Product Divestitures (Details)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/IncomeTaxesDetails" xlink:title="0613 - Disclosure - Income Taxes (Details)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/ContingenciesAndOtherMattersDetails" xlink:title="0614 - Disclosure - Contingencies and Other Matters (Details)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:title="0616 - Disclosure - Significant Customers and Concentration of Credit Risk (Details)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/FairValueMeasurementsTables" xlink:title="0517 - Disclosure - Fair Value Measurements (Tables)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/FairValueMeasurementsDetails" xlink:title="0617 - Disclosure - Fair Value Measurements (Details)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/FairValueMeasurementsDetailsTextual" xlink:title="06172 - Disclosure - Fair Value Measurements (Details Textual)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:title="0130 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_OtherComprehensiveIncomeLossNetOfTax"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_OtherComprehensiveIncomeLossNetOfTax" order="20" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_634668043243711031"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLoss_634668043243711031" order="40" use="optional" weight="1" priority="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/SegmentInformationDetails" xlink:title="0618 - Disclosure - Segment Information (Details)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/SegmentInformation" xlink:title="0218 - Disclosure - Segment Information"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/AccountsReceivable" xlink:title="0205 - Disclosure - Accounts Receivable"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/AccountsReceivableTables" xlink:title="0505 - Disclosure - Accounts Receivable (Tables)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/AccountsReceivableDetails" xlink:title="0605 - Disclosure - Accounts Receivable (Details)">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="20" use="optional" weight="-1" priority="1"/>
<loc xlink:type="locator" xlink:href="hitk-20121031.xsd#hitk_AllowanceForAccountsReceivableReturnAndOtherAllowance" xlink:label="hitk_AllowanceForAccountsReceivableReturnAndOtherAllowance"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="hitk_AllowanceForAccountsReceivableReturnAndOtherAllowance" order="40" use="optional" weight="-1" priority="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="60" use="optional" weight="1" priority="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/AccountsReceivableDetails1" xlink:title="06051 - Disclosure - Accounts Receivable (Details 1)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/AccountsReceivableDetailsTextual" xlink:title="06052 - Disclosure - Accounts Receivable (Details Textual)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/SegmentInformationDetailsTextual" xlink:title="06181 - Disclosure - Segment Information (Details Textual)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/SubsequentEvents" xlink:title="0219 - Disclosure - Subsequent Events"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/SubsequentEventsDetails" xlink:title="0619 - Disclosure - Subsequent Events (Details)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/StockBasedCompensationDetails1" xlink:title="06111 - Disclosure - Stock Based Compensation (Details 1)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/role/FairValueMeasurementsDetailsOne" xlink:title="06171 - Disclosure - Fair Value Measurements (Details 1)"/>
<calculationLink xlink:type="extended" xlink:role="http://www.hitechpharm.com/2011-03-31/role/DocumentDocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information"/>
</linkbase>

↑Top
Filing Submission 0001193125-12-494838   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Tue., May 7, 6:32:00.1am ET